← Benitec Biopharma Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Net Income From Continuing Operations | — | ($8.3m) | ($13.9m) | ($18.2m) | ($19.6m) | ($21.8m) | ($37.9m) | ($41.5m) | |
| Net loss | $2.6m | ($8.3m) | ($13.9m) | ($18.2m) | ($19.6m) | ($21.8m) | ($37.9m) | — | |
| Depreciation, Depletion and Amortization | $158k | $190k | $231k | $167k | $136k | $87k | $66k | $475k | |
| Amortization of right-of-use assets | — | $184k | $193k | $225k | $245k | $256k | $330k | — | |
| Depreciation Amortization Depletion | — | — | — | $392k | $381k | $343k | $396k | $475k | |
| Share-based Payment Arrangement, Noncash Expense | — | $237k | $634k | $870k | $452k | $830k | $17.4m | $26.3m | |
| Share-based Payment Arrangement, Expense | — | $237k | $634k | $870k | $452k | $830k | $17.4m | $26.3m | |
| Share-based compensation expense | $672k | $237k | $634k | $870k | $452k | $830k | $17.4m | $26.3m | |
| Other Nonoperating Income (Expense) | — | $34k | $37k | ($79k) | ($30k) | ($204k) | ($131k) | — | |
| Nonoperating Income (Expense) | — | $7k | ($286k) | ($354k) | ($481k) | $739k | $3.8m | — | |
| Change In Working Capital | — | — | — | $1.0m | $714k | $1.2m | ($2.7m) | ($5.0m) | |
| Trade and other receivables | $607k | $2.4m | $28k | $1k | ($50k) | ($176k) | $197k | — | |
| Change In Receivables | — | — | — | $1k | ($50k) | ($176k) | $197k | $1k | |
| Trade and other payables | $740k | ($1.7m) | $55k | $1.1m | $1.4m | $941k | ($2.4m) | — | |
| Change In Payables And Accrued Expense | — | — | — | $1.1m | $1.4m | $980k | ($2.5m) | ($4.0m) | |
| Accrued employee benefits | ($15k) | $57k | $121k | $80k | $73k | $39k | ($81k) | — | |
| Change In Accrued Expense | — | — | — | — | $73k | $39k | ($81k) | $116k | |
| Prepaid and other assets | — | ($457k) | ($4k) | $62k | ($414k) | $645k | ($111k) | — | |
| Change In Other Current Liabilities | — | — | — | ($196k) | ($252k) | ($275k) | ($356k) | ($338k) | |
| Net Cash Provided by (Used in) Operating Activities | $4.8m |
($7.5m)
-257.31%
|
($12.8m)
-70.30%
|
($15.9m)
-23.90%
|
($18.0m)
-13.29%
|
($19.4m)
-7.72%
|
($23.6m)
-21.57%
|
($19.8m)
+16.09%
|
|
| Cash flows from investing activities: | |||||||||
| Gain (Loss) on Disposition of Property Plant Equipment | — | ($1k) | — | — | — | — | — | $1k | |
| Payments to Acquire Property, Plant, and Equipment | ($404k) | $95k | $221k | $13k | $1k | $179k | $18k | ($26k) | |
| Unrealized Gain (Loss) on Investments | — | ($1k) | $16k | ($11k) | ($3k) | ($1k) | $0 | $0 | |
| Net Cash Provided by (Used in) Investing Activities | ($400k) | ($94k) | ($221k) | ($13k) | ($1k) | ($179k) | ($18k) | ($26k) | |
| Cash flows from financing activities: | |||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | $764k | — | |
| Issuance Of Capital Stock | — | — | — | $0 | $17.9m | $70.9m | $30.5m | $65.5m | |
| Proceeds from Issuance of Common Stock | — | $2.2m | $25.8m | — | $17.9m | $73.9m | $30.5m | $65.5m | |
| Common Stock Issuance | — | — | — | $0 | $17.9m | $70.9m | $30.5m | $65.5m | |
| Deemed dividend | — | — | — | — | — | $619k | $0 | — | |
| Net Other Financing Charges | — | — | — | — | ($1.9m) | ($5.9m) | ($2.3m) | ($6.3m) | |
| Net Cash Provided by (Used in) Financing Activities | — | $1.8m |
$22.5m
+1172.43%
|
— | $16.0m |
$68.0m
+324.78%
|
$70.5m
+3.61%
|
$101.5m
+43.97%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | ($15.7m) | ($1.6m) | $48.4m | $46.9m | $185.1m | |
| Beginning Cash Position | — | — | — | $19.8m | $4.1m | $2.5m | $50.9m | $103.4m | |
| Cash, cash equivalents, and restricted cash, beginning of period | — | — | $19.8m | $4.1m | $2.5m | $50.9m | $97.9m | — | |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | — | — | $499k | $204k | $412k | ($8k) | $49k | — | |
| Net increase in cash, cash equivalents, and restricted cash | — | — | $10.0m | ($15.7m) | ($1.6m) | $48.4m | $46.9m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $4.1m | $2.5m | $50.9m | $97.9m | $185.1m | |
| Effect Of Exchange Rate Changes | — | — | — | $204k | $412k | ($8k) | $49k | ($233k) | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Operating Lease, Expense | — | — | — | — | — | — | $400k | — | |
| Gain on extinguishment of liabilities | — | — | — | — | — | $0 | ($764k) | — | |
| Initial measurement of operating lease right-of-use assets and liabilities | — | ($579k) | — | — | — | $0 | $255k | — | |
| Re-measurement of operating lease right-of-use assets and liabilities | — | — | $0 | $794k | $0 | $0 | $666k | — | |
| Additional Financial Items | |||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | — | ($88k) | ($333k) | ($232k) | ($415k) | $40k | ($71k) | — | |
| General and Administrative Expense | — | $5.6m | $6.5m | $6.6m | $6.4m | $7.0m | $23.4m | — | |
| Operating Expenses | — | $8.4m | $13.7m | $17.9m | $19.2m | $22.5m | $41.8m | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | $97k | $59k | $73k | $75k | $0 | — | — | |
| Unrealized loss on investment | $21k | $1k | ($16k) | $10k | $3k | $1k | $0 | — | |
| Lease liabilities | — | ($174k) | ($192k) | ($196k) | ($252k) | ($275k) | ($356k) | — | |
| Proceeds from exercise of pre-funded warrants, Series 2 warrants common warrants | — | — | — | — | — | $3.0m | $42.3m | — | |
| Share and pre-funded warrants issuance transaction costs | — | ($480k) | ($3.2m) | — | ($1.9m) | ($5.9m) | ($2.3m) | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | $0 | $16.0m | $68.0m | $70.5m | $101.5m | |
| Cash Flow From Continuing Investing Activities | — | — | — | ($13k) | ($1k) | ($179k) | ($18k) | ($26k) | |
| Change In Other Working Capital | — | — | — | $80k | $73k | — | — | — | |
| Change In Payable | — | — | — | $1.1m | $1.4m | $941k | ($2.4m) | ($4.0m) | |
| Change In Prepaid Assets | — | — | — | $62k | ($414k) | $645k | ($111k) | ($751k) | |
| Changes In Cash | — | — | — | ($15.9m) | ($2.0m) | $48.4m | $46.9m | $81.7m | |
| End Cash Position | — | — | — | $4.1m | $2.5m | $50.9m | $97.9m | $185.1m | |
| Financing Cash Flow | — | — | — | $0 | $16.0m |
$68.0m
+324.78%
|
$70.5m
+3.61%
|
$101.5m
+43.97%
|
|
| Free Cash Flow | — | — | — | ($15.9m) | ($18.0m) | ($19.6m) | ($23.6m) | ($19.8m) | |
| Investing Cash Flow | — | — | — | ($13k) | ($1k) | ($179k) | ($18k) | ($26k) | |
| Net PPE Purchase And Sale | — | — | — | ($13k) | ($1k) | ($179k) | ($18k) | ($26k) | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | $3.0m | $42.3m | $20.7m | |
| Purchase Of PPE | — | — | — | ($13k) | ($1k) | ($179k) | ($18k) | ($26k) | |
| Stock Based Compensation | — | — | — | $870k | $452k | $830k | $17.4m | $26.3m | |
| Unrealized Gain Loss On Investment Securities | — | — | — | $10k | $3k | $1k | $0 | $0 | |
| Change In Cash Supplemental As Reported | — | — | — | ($15.7m) | ($1.6m) | $48.4m | $46.9m | — |